Loading...
FYB logo

Formycon Community

XTRA:FYB Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 19 Fair Values set on narratives written by author

Community Investing Ideas

FYB logo
Formycon

New Approvals And Regional Expansion Will Create Future Opportunities

Key Takeaways Waiving the Phase III study for FYB206 cuts significant R&D costs, improving net margins and freeing capital for other uses. Strategic regional expansions and targeted product introductions, like the FYB201 syringe, boost market penetration and revenue potential.
View narrative
€35.69
FV
32.5% undervalued intrinsic discount
22.08%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
4 months ago author updated this narrative